Welcome to our dedicated page for XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock news (Ticker: XOMAP), a resource for investors and traders seeking the latest updates and insights on XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock stock.
XOMA Corporation (NASDAQ: XOMA) is a biotechnology royalty aggregator that acquires future economic rights associated with pre-commercial therapeutic candidates licensed to pharmaceutical or biotech companies. The company has a diverse portfolio of assets, including XACIATO™ for bacterial vaginosis treatment and OJEMDA™ for pediatric low-grade glioma treatment. XOMA's recent acquisitions from Daré Bioscience and Day One Biopharmaceuticals have expanded its commercial assets and potential royalties. With a strategic approach to capital deployment and a focus on driving sustainable free cash flow, XOMA aims to contribute to improving human health through innovative therapies.
XOMA reported its first quarter 2024 financial results, earning a $9 million milestone with the FDA approval of OJEMDA™, gaining $9.5 million from Kinnate acquisition, expanding its portfolio, and initiating a $50 million stock repurchase program. The company also reported $1.5 million in total revenues for Q1 2024.
XOMA has acquired an economic interest in three women's health assets from Daré Bioscience, Inc., for $22 million upfront. The assets include XACIATO™ (clindamycin phosphate) vaginal gel, Ovaprene®, and Sildenafil Cream. XACIATO™ is FDA-approved for treating bacterial vaginosis, with commercial activities initiated by Organon in 2023. XOMA aims to create additional value for shareholders with these acquisitions.
FAQ
What is the current stock price of XOMA Royalty Corporation 8.625% Series A Cumulative Perpetual Preferred Stock (XOMAP)?
What does XOMA Corporation do?
What are some of XOMA's recent achievements?
How does XOMA drive sustainable free cash flow?